Skip to main content

Table 3 Comparison of BMI, HbA1c, FPG, Basal and Bolus Insulin Doses at Baseline and 26 weeks after IDeg Treatment by Gender

From: Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population

Characteristics

Baseline

26 weeks

BMI (kg/m2) (SDS)

 Female (n = 13)

17.73 ± 3.897 (0.07 ± 0.97)

18.07 ± 3.882(0.20 ± 0.82)

 Male (n = 17)

16.42 ± 2.885 (− 0.02 ± 0.93)

16.87 ± 2.099(0.16 ± 0.88)

HbA1c (%)

 Female (n = 13)

9.35 ± 1.824

8.37 ± 0.772*

 Male (n = 17)

9.88 ± 2.147

8.78 ± 2.074*

FPG (mg/dL)

 Female (n = 13)

157.77 ± 54.259

108.85 ± 25.980*

 Male (n = 17)

156.29 ± 32.330

109.76 ± 31.126*

Insulin dose (U/kg of body weight/day)

 Basal insulin

  Female (n = 13)

0.45 ± 0.115

0.49 ± 0.136

  Male (n = 17)

0.41 ± 0.148

0.44 ± 0.141*

 Bolus insulin

  Female (n = 13)

0.57 ± 0.212

0.43 ± 0.161*

  Male (n = 17)

0.44 ± 0.193

0.29 ± 0.122*

  1. BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin, SDS Standard Deviation Score
  2. *P < 0.05 versus baseline (paired t-test)